艾塞那肽:致急性胰腺炎的报告美国FDA忠告:艾塞那肽(exenatide)上市后已有一些与该药相关急性胰腺炎的报告。艾塞那肽(商品名Byetta)是首个被认可使用于治疗2型糖尿病的新一类药物。FDA复核了30例上市后用该药治疗而出现急性胰腺炎的病例报告。此30例中有27例至少查明有一种可引起急性胰腺炎发作的危险因素,例如胆石症、严重高甘油三酯血症及饮酒者等。有6 Exenatide: Acute Pancreatitis Report The FDA advised: There have been reports of some acute pancreatitis associated with this drug after the release of exenatide. Exenatide (trade name Byetta) is the first new class of drugs approved for use in the treatment of type 2 diabetes. The FDA reviewed 30 cases of acute pancreatitis treated with this drug after its launch. Twenty-seven of these 30 patients at least identified a risk factor for the onset of acute pancreatitis, such as cholelithiasis, severe hypertriglyceridemia, and drinkers. There are 6